Cadrenal Therapeutics (CVKD) recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic anticoagulant therapy for warfarin-dependent patients with implanted cardiac devices including left ventricular assist devices, LVAD, or for those with rare cardiovascular conditions. “This year has marked significant opportunities and advancements for Cadrenal Therapeutics, with a strong focus on clinical indications,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “The Company has established a targeted plan to advance the clinical development of tecarfarin and, if approved, to commercialize it as a significant improvement for LVAD patients facing challenges with chronic anticoagulation treatments. We look ahead to 2025 and the initiation of the pivotal Phase 3 clinical trial for tecarfarin in LVAD and developing this much-needed therapeutic solution for advanced heart failure patients with implanted LVADs.” 2024 Year-End Highlights: FDA Engagement and Tecarfarin Development: Cadrenal Therapeutics held a Type B meeting with the U.S. Food and Drug Administration FDA regarding the pivotal Phase 3 clinical trial protocol for tecarfarin in LVAD patients. The Company remains in discussion with the FDA to further refine the trial and expects to provide updates on the anticipated trial in Q1 2025…
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio